What it sells
Non-opioid pain therapies.
Business model breakdown
Trigger: what makes them buy now?
UnverifiedDemand for non-opioid chronic pain therapies.
Workflow: what inputs become what output?
SN101 is an iPSC-derived nociceptor cell therapy (IND-enabling); SN102 is an in vivo gene therapy dampening hyperactive nociceptors (lead optimization).
Distribution: how it reaches customers
UnverifiedPreclinical; the site invites partnering enquiries by email.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-12 | Pre-seed | — | — | news.google.com |
| 2026-10-05 | Pre-seed | — | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.